Abstract
Mycobacterium mucogenicum is a recently characterized organism that rarely may cause human infections. This rapidly growing mycobacterium is commonly identified in tap water. Both immunosuppressed and immunocompetent patients may develop infections from Mycobacterium mucogenicum. Some patients have experienced lethal disease, including sepsis. Infections occurring in the skin and soft tissues have been described only after a preceding injury. We present the first case of infection with Mycobacterium mucogenicum occurring in a patient on the TNF-alpha antagonist etanercept and without any prior soft tissue injury.
MeSH terms
-
Anti-Bacterial Agents / therapeutic use
-
Arthritis, Rheumatoid / drug therapy
-
Clarithromycin / therapeutic use
-
Etanercept
-
Female
-
Humans
-
Immunoglobulin G / administration & dosage
-
Immunoglobulin G / adverse effects*
-
Immunosuppressive Agents / administration & dosage
-
Immunosuppressive Agents / adverse effects*
-
Middle Aged
-
Minocycline / therapeutic use
-
Mycobacterium Infections / diagnosis*
-
Mycobacterium Infections / drug therapy
-
Opportunistic Infections / diagnosis*
-
Opportunistic Infections / drug therapy
-
Receptors, Tumor Necrosis Factor / administration & dosage
-
Skin Diseases, Bacterial / diagnosis*
-
Skin Diseases, Bacterial / drug therapy
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors
Substances
-
Anti-Bacterial Agents
-
Immunoglobulin G
-
Immunosuppressive Agents
-
Receptors, Tumor Necrosis Factor
-
Tumor Necrosis Factor-alpha
-
Minocycline
-
Clarithromycin
-
Etanercept